Methylnaltrexone (Bromide)
Methylnaltrexone (Bromide) structure
|
Common Name | Methylnaltrexone (Bromide) | ||
|---|---|---|---|---|
| CAS Number | 73232-52-7 | Molecular Weight | 436.33900 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C21H26BrNO4 | Melting Point | 237-239ºC | |
| MSDS | Chinese USA | Flash Point | N/A | |
| Symbol |
GHS06, GHS09 |
Signal Word | Danger | |
| Name | (4R,4aS,7aR,12bS)-3-(cyclopropylmethyl)-4a,9-dihydroxy-3-methyl-2,4,5,6,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinoline-3-ium-7-one,bromide |
|---|---|
| Synonym | More Synonyms |
| Melting Point | 237-239ºC |
|---|---|
| Molecular Formula | C21H26BrNO4 |
| Molecular Weight | 436.33900 |
| Exact Mass | 435.10500 |
| PSA | 69.59000 |
| LogP | 3.02510 |
| Symbol |
GHS06, GHS09 |
|---|---|
| Signal Word | Danger |
| Hazard Statements | H301-H400 |
| Precautionary Statements | P273-P301 + P310 |
| RIDADR | UN 2811 6.1 / PGIII |
| RTECS | QD0188550 |
|
~%
Methylnaltrexon... CAS#:73232-52-7 |
| Literature: EP2147920 A2, ; Page/Page column 25 ; |
|
~%
Methylnaltrexon... CAS#:73232-52-7 |
| Literature: US2008/214817 A1, ; Page/Page column 2; 6-7 ; |
|
~%
Methylnaltrexon... CAS#:73232-52-7 |
| Literature: US2010/168427 A1, ; Page/Page column 4 ; |
![(4R,4aS,7aR,12bS)-3-(cyclopropylmethyl)-9-((ethoxycarbonyl)oxy)-4a-hydroxy-3-methyl-7-oxo-2,3,4,4a,5,6,7,7a-octahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-3-ium methyl sulfate structure](https://image.chemsrc.com/caspic/215/1082510-80-2.png)
|
Efficacy of pharmacological therapies for the treatment of opioid-induced constipation: systematic review and meta-analysis.
Am. J. Gastroenterol. 108(10) , 1566-74; quiz 1575, (2013) There has been no definitive synthesis of the evidence for any benefit of available pharmacological therapies in opioid-induced constipation (OIC). We conducted a systematic review and meta-analysis t... |
|
|
[Opiate induced constipation--mechanisms, relevance and treatment].
Dtsch. Med. Wochenschr. 138(43) , 2207-11, (2013)
|
|
|
Effects of remifentanil on the esophagogastric junction and swallowing.
Acta Anaesthesiol. Scand. 57(8) , 1002-9, (2013) A recent study demonstrated that reflux is associated with impaired pressure augmentation in the esophagogastric junction (EGJ), caused by diaphragmal contractions during inspiration. It is unknown wh... |
| [14C]-N-Methylnaltrexone bromide |
| MNTX bromide |
| Naltrexone methobromide |
| (-)-naltrexone methyl bromide |
| Relistor |
| Methylnaltrexone (Bromide) |
| MRZ-2663BR |
| MOA-728 |
| Relistor (TN) |
| MNTX |